Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

cylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and LIALDA should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

LIALDA is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (n=535), the most common treatment-related adverse events with LIALDA 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (4 percent, 2.8 percent and 2.8 percent, respectively). Pancreatitis occurred in less than 1 percent of patients during clinical trials and resulted in discontinuation of therapy with LIALDA.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: VTAE ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On February 27, 2015, the Company announced that its ...
(Date:2/27/2015)... -- Following a bipartisan vote in the House Ways ... Medicare DMEPOS Competitive Bidding Improvement Act of 2015 ... a statement praising the Committee,s work and pushing ... "Today,s mark-up of the Competitive Bidding Improvement ... is a critical step forward for this bipartisan, ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... Mass. , July 1 Shire plc (LSE: ... today announced positive data from its long-term extension to its ... alfa), the company,s enzyme replacement therapy for patients with type ... Annual European Working Group on Gaucher Disease (EWGGD) in ...
... Prasco Laboratories announced today that it ... (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured ... private label. Under the terms of a distribution and ... the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg ...
Cached Medicine Technology:Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6Prasco to Market Authorized Generic of ZEGERID® 2
(Date:2/28/2015)... Chicago, IL (PRWEB) February 28, 2015 ... growth, Chunk Fitness has added an additional exercise to ... as the oblique exercise is most commonly known as, ... equipment. , “Rope Pulls” are executed in a relatively ... varying fitness and strength levels. The full description of ...
(Date:2/28/2015)... The Classic Denture Center , ... special. Throughout all of March patients can receive ... service can help overall mouth health and ... may notice certain symptoms that suggest the denture teeth ... include: , 1.    Pain, clicking, and popping in the joints, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... February 28, 2015 For those people ... person, the Mesothelioma Applied Research Foundation (Meso ... Tuesday, March 3, starting at 9:30 AM. , The ... registration. The broadcast can be accessed through any browser ... . , The Symposium is a unique event that ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... 65 year old retired heart surgeon place first in an Ironman Competition? ... less than 13 hours which qualified him for the Kona, Hawaii Ironman. ... ... surgeon Dwight Lundell gave himself the perfect 65th birthday gift. He placed ...
... the iPhone version of its acclaimed mobile charge capture ... makes it easy for physicians to track their patients, ... quickly. ,pMDsoft,s native application is the first charge ... the App Store, so it can be used even ...
... More than half a million babies are born preterm in ... the rise. Late preterm births, or births that occur ... before the mother,s due date), account for more than 70% ... babies, many people are unaware of the serious health problems ...
... , ATLANTIC CITY, N.J., Dec. 10 A letter ... Iraq conflict and recuperating at Walter Reed Army Hospital in Washington, DC ... Atlantic City. , , The letter, detailing ... war injuries and wishing for the chance to take a break from ...
... Mich., Dec. 10 News stories this,afternoon by ... information about Executive Order (EO) budget cuts proposed ... reported:,"Another $5.3 million will be saved by cutting ... the EO cuts do not reduce provider,payments for ...
... holds up, it might lead to cures, researchers say ... identified common genetic mutations between type 1 diabetes and ... stem from a shared underlying mechanism. , The ... triggered by similar environmental factors. , "Our results ...
Cached Medicine News:Health News:Retired Heart Surgeon Dr. Dwight Lundell Celebrates 65th Birthday by Placing First in Arizona Ironman Competition 2Health News:pMDsoft Releases Native Charge Capture Software for iPhone 2Health News:pMDsoft Releases Native Charge Capture Software for iPhone 3Health News:pMDsoft Releases Native Charge Capture Software for iPhone 4Health News:pMDsoft Releases Native Charge Capture Software for iPhone 5Health News:Late preterm births present serious risks to newborns 2Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Genetic Link Between Type 1 Diabetes, Celiac Disease Seen 2Health News:Genetic Link Between Type 1 Diabetes, Celiac Disease Seen 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: